

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\*

NextCure, Inc.

---

(Name of Issuer)

Common Stock, par value \$0.001 per share

---

(Title of Class of Securities)

---

(CUSIP Number)

12/31/2025

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Simcere Zaiming, Inc.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power  
 338,636.00  
 Shared Voting Power  
 6  
 0.00  
 Sole Dispositive Power  
 7  
 338,636.00  
 Shared Dispositive Power  
 8  
 0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

338,636.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)

9.4 %

12 Type of Reporting Person (See Instructions)

CO

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

Check the appropriate box if a member of a Group (see instructions)

2  (a)

(b)

3 Sec Use Only

4 Citizenship or Place of Organization

CHINA

Sole Voting Power

5  
 338,636.00

Number of Shares Beneficially Owned by Each Reporting Person With: 6 Shared Voting Power

0.00

Sole Dispositive Power

7  
 338,636.00

Shared Dispositive Power

8  
 0.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

9.4 %

Type of Reporting Person (See Instructions)

12

CO

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

### SCHEDULE 13G

#### CUSIP No.

Names of Reporting Persons

1

Simcere Zaiming Pharmaceutical Co., Ltd.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

CHINA

Sole Voting Power

5

338,636.00

Number of Shares

Shared Voting Power

6

0.00

Beneficially Owned by

Sole Dispositive Power

7

338,636.00

Each Reporting Person

Shared Dispositive

With:

8 Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

9.4 %

Type of Reporting Person (See Instructions)

12

CO

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Zaiming Pharmaceutical Co., Ltd. may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

## SCHEDULE 13G

### CUSIP No.

	Names of Reporting Persons
1	Simcere Pharmaceutical Group Limited
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	CHINA
	Sole Voting Power
5	338,636.00
Number of	Shared Voting Power
Shares	6
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	7
Reporting	338,636.00
Person	Shared Dispositive
With:	8
	Power
	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	338,636.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
	Percent of class represented by amount in row (9)
11	9.4 %
	Type of Reporting Person (See Instructions)
12	CO

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Simcere Pharmaceutical Group Limited is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through investment in several intermediate companies. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Pharmaceutical Group Limited may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

# SCHEDULE 13G

## CUSIP No.

Names of Reporting Persons

1

Ren Jinsheng

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

CHINA

Sole Voting Power

5

0.00

Number of  
Shares

Shared Voting Power

6

Beneficially  
Owned by

338,636.00

Each

Sole Dispositive Power

7

Reporting  
Person

0.00

With:

Shared Dispositive

8

Power

338,636.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

9.4 %

Type of Reporting Person (See Instructions)

12

IN

**Comment for Type of Reporting Person:** Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Pharmaceutical Group Limited and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Renhong Tang. Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

# SCHEDULE 13G

## CUSIP No.

1

Names of Reporting Persons

Tang Renhong

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

CHINA

Sole Voting Power

5

0.00

Number of  
Shares

Shared Voting Power

6

Beneficially  
Owned by

338,636.00

Each  
Reporting

Sole Dispositive Power

7

Person

0.00

With:

Shared Dispositive

8

Power

338,636.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

9.4 %

Type of Reporting Person (See Instructions)

12

IN

**Comment for Type of Reporting Person:** Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Mr. Renhong Tang is a director of Simcere Pharmaceutical Group Limited, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and the chief executive officer and sole director of Simcere Zaiming, Inc. Accordingly, Mr. Renhong Tang may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Jinsheng Ren. Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

## SCHEDULE 13G

Item 1.

Name of issuer:

(a)

NextCure, Inc.

Address of issuer's principal executive offices:

(b)

9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705

Item 2.

(a)

Name of person filing:

(i) Simcere Zaiming, Inc., a Delaware corporation ("Simcere Zaiming"), with its principal business address at 20 Acorn Park Dr., Cambridge, MA 02140; (ii) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Jiangsu Zaiming"), is the sole shareholder of Simcere Zaiming, and its

principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; (iii) Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.), a limited liability company incorporated in P. R. China ("Hainan Zaiming"), is the sole shareholder of Jiangsu Zaiming, and its principal business address is at No 20, Yaoguyiheng Road, Xiuying District, Haikou, Hainan, P. R. China; (iv) Simcere Pharmaceutical Group Limited, a company incorporated in Hong Kong ("Simcere Group") and the controlling shareholder of Hainan Zaiming through several intermediate companies, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; (v) Mr. Jinsheng Ren, citizen of People's Republic of China, the chairman of board of directors and an executive director of Simcere Group and a director of Hainan Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; and (vi) Mr. Renhong Tang, citizen of People's Republic of China, a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China. The persons and entities listed in items (i) to (vi) are collectively referred to herein as "Reporting Persons." The Reporting Persons have entered into a joint filing agreement dated August 19, 2025.

Address or principal business office or, if none, residence:

(b) See Item 2(a) above.

Citizenship:

(c) See Item 2(a) above.

Title of class of securities:

(d) Common Stock, par value \$0.001 per share

(e) CUSIP No.:

Item 4. Ownership

Amount beneficially owned:

(a) See Row 9 of the cover page for each Reporting Person. Each of Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this Amendment No.1 to Schedule 13G shall not be deemed to be an admission that the Reporting Persons hereunder are the beneficial owners of any of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Percent of class:

(b) See Row 11 of the cover page for each Reporting Person. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Row 5 of the cover page for each Reporting Person.

(ii) Shared power to vote or to direct the vote:

See Row 6 of the cover page for each Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of the cover page for each Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of the cover page for each Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sincere Zaiming, Inc.

Signature: /s/ Renhong Tang  
Name/Title: Renhong Tang/Chief Executive Officer  
Date: 05/06/2026

Jiangsu Sincere Zaiming Pharmaceutical Co., Ltd.

Signature: /s/ Renhong Tang  
Name/Title: Renhong Tang/Director and Attorney-in-Fact  
Date: 05/06/2026

Sincere Zaiming Pharmaceutical Co., Ltd.

Signature: /s/ Renhong Tang  
Name/Title: Renhong Tang/Chief Executive Officer and  
Chairman of the Board of Directors  
Date: 05/06/2026

Sincere Pharmaceutical Group Limited

Signature: /s/ Jinsheng Ren  
Name/Title: Jinsheng Ren/Chairman and Executive Director  
Date: 05/06/2026

Ren Jinsheng

Signature: /s/ Jinsheng Ren  
Name/Title: Jinsheng Ren  
Date: 05/06/2026

Tang Renhong

Signature: /s/ Renhong Tang  
Name/Title: Renhong Tang  
Date: 05/06/2026

**Comments accompanying signature:** 24 Power of Attorney (incorporated by reference to Exhibit 24 to the Reporting Persons' Schedule 13G filed with the SEC on August 19, 2025). 99.1 Joint Filing Agreement, dated as of August 19, 2025, by and among the Reporting Persons (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on August 19, 2025).